Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Cardiac tumors and masses

Cardiac tumors and masses encompass abnormalities that differ widely in biological origin, behavior, and clinical significance, but share the presence of a formation occupying a heart chamber, involving a valve, growing within the myocardial wall, or affecting the pericardium. The term mass describes an anatomical or imaging finding; the term tumor identifies tissue proliferation requiring further characterization. A thrombus, an infectious vegetation, and a neoplasm may initially appear as additional structures in the same anatomical region, but arise from different processes and require profoundly different therapeutic decisions. Even a normal anatomical variant may mimic a lesion and must be recognized before the finding is attributed pathological significance.
The fundamental distinction separates primary tumors, arising from cardiac or pericardial structures, from secondary involvement by an extracardiac malignancy and from non-neoplastic formations. Among primary tumors, histologically benign forms predominate; however, in an organ where only a few millimeters may separate a mass from a coronary ostium or part of the conduction system, histological benignity is compatible with severe clinical consequences. Size, mobility, site of attachment, and relationship to blood flow contribute to risk alongside the biology of the lesion.

Epidemiological estimates are affected by the rarity of primary neoplasms and differences in the selection of study populations. Autopsy series also detect clinically silent lesions, whereas surgical registries favor symptomatic masses or those considered to warrant resection. In a fourteen-year population-based study in the province of Grosseto, the incidence of primary cardiac tumors was approximately 1.38 cases per 100,000 inhabitants per year; 90.5% of the cases identified were benign. This figure describes that population and ascertainment system and is not a universal estimate applicable to every setting.
Secondary cardiac involvement is overall much more frequent than primary tumors, particularly in oncological and autopsy series. Its clinically recognized frequency depends on cancer stage, survival, and imaging use. In children and fetuses, the histological profile differs from that in adults: rhabdomyomas and fibromas are particularly important, whereas myxoma and papillary fibroelastoma are key diagnoses in adults. Increasing echocardiographic detection of fibroelastomas partly explains differences in the frequency rankings reported across series.

The assessment of cardiac masses therefore rests on integrating clinical probability, anatomy, and tissue characterization. The clinically useful result establishes both the nature of the formation and the risk it poses to the individual patient. An incidental fatty lesion, a valvular mass after stroke, and atrial infiltration in a patient with cancer represent different problems from the first clinical encounter, even when initially described with the same word.

Etiology, pathogenesis, and pathophysiology

For most sporadic cardiac neoplasms, the initiating etiological event remains unknown. Their rarity makes it difficult to distinguish chance associations, predispositions, and causal determinants. Common atherosclerosis risk factors must not automatically be extrapolated to cardiac tumorigenesis. Conversely, well-documented genetic associations exist in defined subgroups: Carney complex may include multiple or recurrent cardiac myxomas, whereas tuberous sclerosis is strongly associated with rhabdomyomas, especially when they are multiple and detected in fetal life or childhood.
In Carney complex, inactivating pathogenic variants of PRKAR1A affect a regulatory subunit of protein kinase A, altering the cellular response to cyclic AMP-mediated signaling. This defect predisposes to myxomatous lesions and other manifestations, including endocrine disorders. Recognizing the condition changes the significance of an apparently isolated mass because it introduces the risk of lesions at other sites and new manifestations over time. However, a single myxoma in an adult does not, by itself, establish a hereditary syndrome.

In tuberous sclerosis, alterations in TSC1 or TSC2 impair the hamartin–tuberin complex and regulation of the mTOR pathway, promoting cell growth and hamartoma formation. Cardiac rhabdomyoma occurs within this biological context and has a distinctive natural history, with frequent regression after birth. This course clearly differentiates hamartomatous growth from an infiltrative adult neoplasm. Understanding the molecular mechanism has also enabled selective use of mTOR inhibitors in symptomatic cardiac disease following specialist assessment.
Other tumors arise from mesenchymal, vascular, adipose, or hematolymphoid tissues. In sarcomas, infiltrative proliferation can replace myocardium and cross anatomical planes; in lymphomas, cardiac involvement reflects a hematological neoplasm whose definition requires immunophenotyping and appropriate systemic evaluation. The category of malignant cardiac tumors therefore encompasses diseases with markedly different treatments and treatment sensitivities. The metastatic potential of paragangliomas must likewise be evaluated according to their specific biology: an apparently localized lesion does not justify declaring that potential absent.

Cardiac metastases reach the heart through hematogenous spread, lymphatic dissemination, direct extension from adjacent structures, or growth along the venous system. The pericardium is frequently involved in secondary disease, including via the mediastinal lymphatic network. Some cancers may extend along the venae cavae into the right atrium or along the pulmonary veins into the left atrium. In such cases, an intracavitary mass represents the terminal segment of a disease process that must be traced throughout its anatomical course.
Lymphatic invasion impairs pericardial fluid reabsorption; increased permeability and vascular injury promote further fluid accumulation and potentially a hemorrhagic component. Within the myocardium, infiltration disrupts contractility and propagation of electrical impulses. A pre-existing extracardiac malignancy increases the likelihood of secondary cardiac involvement, but may also promote thrombosis or infection: the oncological context informs clinical reasoning without replacing characterization of the finding.

Non-neoplastic masses have a different pathogenesis. An intracardiac thrombus forms when altered blood flow, endocardial injury or dysfunction, and prothrombotic conditions promote deposition of fibrin and blood components. Atrial fibrillation, ventricular akinesia, and intracardiac devices create different thrombogenic settings. Infective vegetations instead arise from microbial colonization of endocardial surfaces accompanied by deposition of thrombotic material and an inflammatory response; sterile vegetations are mainly associated with prothrombotic or autoimmune conditions. A tumor surface may itself become covered with thrombus, producing a mass composed of different tissues and increasing the potential for embolization.

Functional consequences depend primarily on the lesion's relationship to the circulation. A mobile atrial formation may encroach upon a valve orifice and cause dynamic obstruction that varies during the cardiac cycle and with body position. Increased upstream pressure causes venous congestion and reduces filling of the downstream chamber; severe cases reduce cardiac output and systemic perfusion. Infiltration or attachment to the valve apparatus may instead prevent leaflet coaptation and cause regurgitation. Thus, the same absolute size has different effects in a large chamber, an outflow tract, or near an ostium.

Friability and exposure to blood flow constitute a second pathophysiological dimension. Fragments of the mass or its surface thrombus may detach: material from the left-sided chambers enters the systemic circulation, whereas material from the right-sided chambers reaches the pulmonary arterial bed. A communication allowing a right-to-left shunt can permit paradoxical embolism. Intramural lesions, by contrast, may disrupt conduction and create electrical heterogeneity conducive to arrhythmias, even when they occupy little intracavitary space.
Some masses cause systemic effects independently of obstruction. In myxoma, mediators such as interleukin-6 contribute to fever, the acute-phase response, and constitutional symptoms; a functional paraganglioma may release catecholamines, causing adrenergic manifestations and blood-pressure instability. These mechanisms explain why a cardiac neoplasm may initially present as an inflammatory, neurological, or endocrine problem.

Clinical manifestations

The medical history should establish how symptoms began and their relationship to posture, exertion, or heart rhythm. Gradually progressive dyspnea may reflect valvular obstruction, ventricular dysfunction, or pericardial effusion; episodes of presyncope or syncope, especially when associated with postural changes, make mobile interference with blood flow plausible. Palpitations, episodes of tachycardia, or new-onset bradycardia suggest electrical involvement but require rhythm documentation. The absence of symptoms remains compatible with a potentially emboligenic lesion and does not remove the need for risk assessment.
A history of stroke, transient ischemic attack, or peripheral embolism may precede discovery of the mass. The chronology, affected territories, and any recurrence must be established. In a patient with sudden dyspnea, pleuritic pain, or syncope, a right-sided mass may accompany pulmonary embolism. The search for a cardiac source must nevertheless account for other possible causes of the vascular event: detecting a mass and demonstrating that it caused an embolism are conceptually distinct steps.

Fever, fatigue, arthralgia, weight loss, and sweating may accompany cardiac tumors, infections, or systemic malignancies. These findings must be correlated with blood cultures, inflammatory findings, cancer history, immunosuppression, and the presence of prostheses or catheters. A thorough history also covers myocardial infarction, cardiomyopathy, atrial fibrillation, venous thromboembolism, and anticoagulant therapy, since these factors alter the probability of a thrombotic formation. Previous cardiac procedures may explain foreign material, postoperative structures, or device-adherent thrombi.
In young people, with multiple lesions, or following recurrence, a family history of myxomas or other neoplasms, skin signs, and endocrine history become particularly relevant. In children, neurological, cutaneous, and renal manifestations compatible with a syndromic condition should be sought. In newborns, a mass may manifest as arrhythmia, feeding difficulties, tachypnea, or poor growth; in the fetus, echocardiography may detect it before any extrauterine manifestations.

Physical examination starts with blood pressure, heart rate and rhythm, oxygen saturation, peripheral perfusion, and signs of instability. Jugular venous distension, edema, and hepatomegaly suggest impaired venous return or right-sided heart failure; pulmonary crackles suggest pulmonary congestion. Auscultation may reveal murmurs due to obstruction or regurgitation and, less commonly, sounds associated with mass movement. The so-called tumor plop may accompany a myxoma, but it is frequently absent, and its presence cannot replace imaging.
The combination of hypotension, tachycardia, raised venous pressure, and consistent echocardiographic findings should prompt consideration of cardiac tamponade. Neurological and peripheral vascular examinations look for consequences of embolism, while the skin and mucous membranes may offer infectious or syndromic clues. Overall, physical findings mainly reflect the anatomical and pathophysiological effects of the mass; on their own, they rarely identify its histology.

Investigations and diagnosis

Clinical suspicion usually leads to transthoracic echocardiography, which can confirm the presence of the formation, locate it, and assess its effects on cardiac function. The examination should establish the involved chamber or wall, size, number of lesions, attachment site, mobility, relationships to valves, and any effusion. Doppler imaging documents flow obstruction and regurgitation; biventricular assessment distinguishes the effects of the mass from underlying heart disease that may have promoted its formation. A finding seen in only one view should be confirmed before being accepted as real.

Transesophageal echocardiography provides further characterization particularly of valvular, atrial, and left atrial appendage lesions or masses with a poorly defined attachment. It is advantageous for small, highly mobile formations, including papillary fibroelastoma, and for evaluating prostheses and devices. Three-dimensional reconstructions clarify spatial relationships; ultrasound contrast agents can improve endocardial definition and provide information about vascularity. These methods address specific questions and are selected based on location and the quality of the initial examination.

Cardiac magnetic resonance imaging adds tissue characterization. Cine sequences, T1 and T2 weighting, fat suppression, perfusion, and post-gadolinium acquisitions can describe fat content, water, fibrosis, hemorrhage, necrosis, and contrast-enhancement behavior. Lack of vascularization supports a thrombotic nature, while perfusion and enhancement patterns suggest different tissue components. However, an organized thrombus may have less typical appearances, just as a necrotic neoplasm may contain extensive nonperfused areas.
MRI is especially useful for defining myocardial extension and relationships to surrounding structures, but has limitations for very small, rapidly moving formations. The signal in any one sequence is not a histological diagnosis. Correct interpretation depends on concordance between clinical data, location, morphology, and behavior across acquisitions, using a multiparametric approach.

Computed tomography complements other modalities in assessing calcifications, fat content, and relationships to coronary arteries, great vessels, and extracardiac structures. It may be preferred when MRI is impracticable and, with appropriate protocols, provides anatomical information useful for surgical planning. Chest–abdomen–pelvis CT has a role in searching for an extracardiac primary malignancy and staging. Fluorodeoxyglucose PET is selected when metabolic information, identification of additional sites, or localization of a biopsy target is needed; uptake can also occur in inflammation and requires appropriate preparation to minimize physiological myocardial signal.

Blood tests are guided by the suspected diagnosis. Blood count, inflammatory markers, and organ-function tests characterize the setting and prepare for procedures and treatment, but no universal circulating biomarker can identify a cardiac tumor. Blood cultures are required when endocarditis is suspected; targeted endocrine investigations must precede procedures on lesions suspected to be functioning paragangliomas. Indiscriminate testing for tumor markers does not replace imaging and histology.
There is no single international criteria system that automatically assigns every cardiac mass to a histological type. In line with the approach set out in cardiovascular imaging documents, the lesion must be documented, its site and features characterized, and those findings integrated with the clinical context. Suspicion of malignancy increases with tissue invasion, irregular margins, a broad attachment base, growth, and extracardiac sites, but no individual feature amounts to pathological confirmation.

The differential diagnosis includes thrombi, vegetations, anatomical variants, cysts, fat deposits, and calcific processes, as well as tumors. A cardiac myxoma is often attached to the interatrial septum near the fossa ovalis, whereas atrial thrombus is more typically associated with stasis in the atrial appendage. These associations are useful for estimating probability, not as absolute exclusions. Histological confirmation is obtained from the surgical specimen in resected masses; preliminary biopsy is reserved for cases where its result changes management and tissue sampling carries acceptable risk.

Disease characterization and assessment of extent

When imaging suggests a neoplasm, the next step is to establish which information is still needed to select treatment. It is necessary to define wall infiltration, valvular involvement, relationships with coronary arteries and great vessels, and the presence of extracardiac disease. A circumscribed lesion and a mass encasing vital structures may share the same histological type but have entirely different prospects for resection. The description must therefore explicitly address anatomical resectability rather than confusing it with size alone.
Staging depends on the identified neoplasm: sarcoma, lymphoma, and metastasis each follow their own oncological staging systems and pathways. If accessible extracardiac lesions are present, biopsy at those sites may provide the required tissue while avoiding a riskier cardiac procedure. For masses suspicious for lymphoma, obtaining material suitable for immunophenotyping is particularly important; for sarcomas, specialist pathological review and, where appropriate, molecular testing may alter classification and treatment options.

Cardiac tissue sampling requires multidisciplinary planning. Risks of embolization, perforation, tamponade, and bleeding must be considered, especially in highly vascular lesions. A mobile, likely resectable left-sided mass may proceed to surgery without percutaneous biopsy; an infiltrative right-sided lesion may pose a different problem. Cytology of a pericardial effusion can also be informative in the appropriate setting, but a negative result does not rule out every form of neoplastic involvement.
Assessment of organ impact includes ventricular function, consequences of embolism, nutritional status, functional capacity, and renal and hepatic reserve. Patients considered for potentially cardiotoxic anticancer treatments also require a baseline assessment of cardiac function. Suspected hereditary predisposition warrants genetic counseling and targeted syndromic investigations; subsequent follow-up will differ from that of an isolated sporadic lesion.

Treatment and prognosis

Treatment is determined by the nature of the mass and the clinical priority. Cardio-oncology guidelines emphasize multidisciplinary decision-making involving cardiology, imaging, cardiac surgery, oncology or hematology, and pathology. In the presence of tamponade, critical obstruction, severe arrhythmia, or an evolving embolic event, stabilization and treatment of the complication take precedence over tests that would not change immediate management. In stable patients, a reasoned characterization can instead be completed, avoiding procedures that introduce risk without a corresponding decision-making benefit.

For many benign cardiac tumors, resection is definitive treatment when symptoms, embolic risk, obstruction, or substantial diagnostic uncertainty are present. An operable myxoma generally warrants prompt surgical assessment because drug treatment alone eliminates neither the mass nor the risk of fragmentation. For fibroelastomas, decisions take into account embolic events, left-sided location, mobility, lesion features, and operative risk; a size threshold alone cannot determine management.
Surgery aims to remove abnormal tissue while preserving valvular and myocardial structures as far as possible. The feasibility of conservative resection depends on attachment and extent. Anticoagulation may treat a concomitant thrombotic component or a separate indication, but it is not a pharmacological substitute for removal of an emboligenic tumor.

A surveillance strategy is appropriate for certain well-characterized, asymptomatic lesions without functional consequences if the balance between disease risk and intervention risk favors it. Follow-up frequency is adapted to histological type or presumed diagnosis, site, and stability over time; there is no single interval appropriate for all masses. Lipomatous hypertrophy of the interatrial septum, when recognized by its typical features, often requires only assessment and management of associated conditions. In pediatric rhabdomyoma, the tendency to regress frequently justifies monitoring, whereas significant obstruction or arrhythmias may require targeted drug therapy or surgery.

In cardiac sarcomas, local disease control may require resection and, depending on histological type, margins, extent, and patient condition, systemic treatment or radiotherapy. Infiltration of vital structures often makes clear margins difficult to obtain. Decisions concerning neoadjuvant or adjuvant sequencing are based mainly on selected case series and experience with soft-tissue sarcomas, with limitations stemming from the scarcity of disease-specific studies. Any potentially actionable molecular alterations must be interpreted by an expert team without automatically assuming that every theoretical target will translate into cardiac treatment efficacy.
Cardiac lymphoma, by contrast, requires systemic hematological treatment guided by histological and immunophenotypic classification. Surgery may be useful for obtaining tissue or addressing selected mechanical problems, but anatomical removal of the mass is not normally the mainstay of treatment. Early monitoring must account for cardiac compromise and rapid changes in mass size during treatment response.

In secondary cardiac involvement, management depends on the primary malignancy, disease burden, and the prospects for systemic control. Anticancer treatments, selected radiotherapy, and procedures to relieve obstruction may be used for different purposes. Pericardial metastases may require urgent drainage or strategies to limit effusion recurrence. The choice between pericardiocentesis, prolonged drainage, and a pericardial window takes account of stability, procedural risk, and oncological outlook.
A thrombotic formation is instead treated according to its location and cause, with anticoagulation and, in selected circumstances, reperfusion therapies or removal. Infective vegetations require antimicrobial therapy and evaluation of surgical indications; indiscriminate anticoagulation of a valvular mass without defining the underlying context may expose the patient to unjustified risk. Accurate etiological diagnosis is therefore already an integral part of treatment.

Prognosis is extremely heterogeneous. Many benign lesions, when completely resected, allow prolonged survival and good quality of life, but outcomes also depend on damage already sustained, comorbidities, and any recurrences. Surgical myxoma series document generally favorable results, while highlighting the need to consider late arrhythmias and new cardiovascular events. Primary malignant tumors generally carry a poorer prognosis, determined by histology, metastases, resectability, and treatment response; lymphoma may follow a different course from sarcoma. In metastatic disease, the prognostic significance of cardiac involvement must be interpreted in the context of the overall malignancy.
Follow-up must assess both lesion control and recovery of function. After resection, monitoring seeks residual disease or recurrence, valve insufficiency, and rhythm disorders; in hereditary conditions, surveillance extends to other manifestations of the syndrome. A clinically important change warrants reassessment even if the scheduled follow-up visit is still some time away.

Complications

The most important complications arise from the interaction of the mass with blood flow, the valvular apparatus, myocardium, and pericardium. Embolism may be the first manifestation of an otherwise silent lesion and depends on tissue fragility, mobility, and surface thrombosis. In the systemic circulation it may cause stroke, acute limb ischemia, visceral infarction, or, less commonly, coronary occlusion. In the pulmonary circulation it may cause pulmonary embolism and right ventricular overload. An embolic event involving tumor material may have consequences that persist after the cardiac source is removed; follow-up must therefore consider the affected territory as well as the heart.

Obstruction of an orifice or outflow tract may progress from exertional symptoms to marked congestion, syncope, and circulatory collapse. Mobile masses may cause rapid changes in the degree of obstruction, whereas infiltrative lesions tend to impair function progressively. Valvular regurgitation adds volume overload; myocardial invasion reduces contractile capacity. These mechanisms may converge in heart failure, without lesion size alone predicting the severity of hemodynamic compromise.
Arrhythmias include atrial or ventricular tachyarrhythmias and conduction disturbances. Their origin may be direct, through tissue infiltration or distortion, or indirect, through dilation and increased intracardiac pressure. Involvement of the conduction system may cause advanced block; an arrhythmogenic ventricular substrate may contribute to sudden death even with histologically benign lesions.

Tamponade develops when increased intrapericardial pressure impedes cardiac filling. The rate of fluid accumulation is crucial: a rapidly progressive effusion may become critical at a lower volume than one tolerated during chronic accumulation. Hemorrhage from vascularized tumor tissue and lymphatic obstruction are possible mechanisms. Persistent pericardial involvement may also contribute to constrictive physiology, while invasion or compression of the great vessels may cause syndromes of impaired venous return.

Malignant neoplasms may be complicated by local progression, necrosis, bleeding, and metastatic spread; benign masses may recur, especially in predisposed patients or after incomplete resection. Treatment-related complications form a separate category: surgery, anticoagulation, and anticancer therapies expose patients to procedural, hemorrhagic, and treatment-specific toxicity risks, respectively. Their impact must be weighed against the actual risk posed by the lesion. Effective management therefore requires ongoing reassessment of the balance between disease control, cardiovascular function, and treatment tolerability.

References
  1. Tyebally S et al. Cardiac Tumors: JACC CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2020;2(2):293-311.
  2. Basso C et al. Cardiac masses and tumours. Heart. 2016;102(15):1230-1245.
  3. Cresti A et al. Incidence rate of primary cardiac tumors: a 14-year population study. Journal of Cardiovascular Medicine. 2016;17(1):37-43.
  4. Angeli F et al. Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2024;6(6):847-862.
  5. Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229-4361.
  6. Cohen A et al. EACVI recommendations on cardiovascular imaging for the detection of embolic sources: endorsed by the Canadian Society of Echocardiography. European Heart Journal - Cardiovascular Imaging. 2021;22(6):e24-e57.
  7. Mousavi N et al. Assessment of Cardiac Masses by Cardiac Magnetic Resonance Imaging: Histological Correlation and Clinical Outcomes. Journal of the American Heart Association. 2019;8(1):e007829.
  8. Tamin SS et al. Prognostic and Bioepidemiologic Implications of Papillary Fibroelastomas. Journal of the American College of Cardiology. 2015;65(22):2420-2429.
  9. Jiang CX et al. Long-term outcome of patients with atrial myxoma after surgical intervention: analysis of 403 cases. Journal of Geriatric Cardiology. 2019;16(4):338-343.
  10. Bussani R et al. Cardiac metastases. Journal of Clinical Pathology. 2007;60(1):27-34.
  11. Kirschner LS et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nature Genetics. 2000;26(1):89-92.
  12. Northrup H et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology. 2021;123:50-66.
  13. Levine GN et al. Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association. Circulation. 2022;146(15):e205-e223.
  14. Delgado V et al. 2023 ESC Guidelines for the management of endocarditis. European Heart Journal. 2023;44(39):3948-4042.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.